C
Christopher D. Watt
Researcher at University of Pennsylvania
Publications - 32
Citations - 903
Christopher D. Watt is an academic researcher from University of Pennsylvania. The author has contributed to research in topics: Myeloid leukemia & DNA methyltransferase. The author has an hindex of 15, co-authored 30 publications receiving 682 citations. Previous affiliations of Christopher D. Watt include Hospital of the University of Pennsylvania.
Papers
More filters
Journal ArticleDOI
Clonal Selection with RAS Pathway Activation Mediates Secondary Clinical Resistance to Selective FLT3 Inhibition in Acute Myeloid Leukemia
Christine M. McMahon,Timothy T. Ferng,Jonathan Canaani,Eunice S. Wang,Jennifer J.D. Morrissette,Dennis J. Eastburn,Maurizio Pellegrino,Robert Durruthy-Durruthy,Christopher D. Watt,Saurabh Asthana,Elisabeth A. Lasater,Elisabeth A. Lasater,Rosa Anna DeFilippis,Cheryl A.C. Peretz,Lisa H F McGary,Safoora Deihimi,Aaron C Logan,Selina M. Luger,Neil P. Shah,Martin Carroll,Catherine C. Smith,Alexander E. Perl +21 more
TL;DR: Dynamic and complex changes in clonal architecture underlying response and resistance to mutation-selective tyrosine kinase inhibitor therapy in AML are illustrated.
Journal ArticleDOI
Frequency of EGFR and KRAS mutations in patients with non small cell lung cancer by racial background: Do disparities exist?
Joshua Bauml,Rosemarie Mick,Yu Zhang,Christopher D. Watt,Anil Vachani,Charu Aggarwal,Tracey L. Evans,Corey J. Langer +7 more
TL;DR: It is found that race was statistically significantly associated with EGFR mutation, but not KRAS mutational status, even after adjusting for smoking status and gender.
Journal ArticleDOI
Evaluation of EGFR mutation status in cytology specimens: an institutional experience.
Dara L. Aisner,Charuhas Deshpande,Zubair W. Baloch,Christopher D. Watt,Leslie A. Litzky,B. Malhotra,Antonia R. Sepulveda,Corey J. Langer,Tracey L. Evans,Vivianna M. Van Deerlin +9 more
TL;DR: The data indicate that CB specimens provide an alternative source for molecular evaluation of NSCLC, and that tumor percentage may be more important than specimen size and/or DNA yield in determining the suitability of these specimens for testing.
Journal ArticleDOI
Gilteritinib induces differentiation in relapsed and refractory FLT3-mutated acute myeloid leukemia
Christine M. McMahon,Jonathan Canaani,Bryan Rea,Rachel L. Sargent,Julianne Qualtieri,Christopher D. Watt,Jennifer J.D. Morrissette,Martin Carroll,Martin Carroll,Alexander E. Perl +9 more
TL;DR: O Ongoing clonal hematopoiesis is ubiquitous during gilteritinib therapy and may promote genetic evolution and drug resistance in FLT3 -mutated AML.
Journal ArticleDOI
Educating future leaders of medical research: analysis of student opinions and goals from the MD-PhD SAGE (Students' Attitudes, Goals, and Education) survey.
TL;DR: Findings indicate that students have clinical interests that develop over time, a variety of future career goals, and ambivalence concerning the appropriate balance of clinical and research activities.